Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

Each year, Phesi releases an analysis of the world’s most studied diseases. The survey includes data from the 67,569 ...

In combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) ...

We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now. In this article, we are going to take a look at ...

We recently compiled a list of the 10 Mid-Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Nuvalent, Inc.

Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) have been assigned an average recommendation of “Buy” ...

These drugs, discovered decades ago, continue to save lives today, but more recent research has led to the development of ...

Jones Trading reiterated a Buy rating on ORIC Pharmaceuticals stock with a price target of $17.00, as shares traded at $11.23. The stock has shown remarkable momentum, gaining over 20% in the past ...

Dr Zaheer Mangera discusses the evolution of the neoadjuvant lung cancer pathway and notable changes to the TNM standards.

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.